The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes

Diagnostic Pathology

Volumn 6, Issue 1, 2011, Pages

  Lee, Wonae ^a  

^a Dankook University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD66 ANTIGENS; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY; FATTY LIVER; HUMAN; LIVER CELL; METABOLISM; MIDDLE AGED; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOLOGICAL MARKERS; BIOPSY; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; HEPATOCYTES; HUMANS; MIDDLE AGED; OBESITY, MORBID;

EID: 79955755233     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-6-40     Document Type: Article

References (32)

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846.
2. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000, (113):3-13.
3. Obrink B. CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol 1997, 9(5):616-626.
4. Barnett TR, Kretschmer A, Austen DA, Goebel SJ, Hart JT, Elting JJ, Kamarck ME. Carcinoembryonic antigens: alternative splicing accounts for the multiple mRNAs that code for novel members of the carcinoembryonic antigen family. J Cell Biol 1989, 108(2):267-276.
5. Cruz PV, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K. Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma. Cancer 2005, 104(2):354-360.
6. Nollau P, Prall F, Helmchen U, Wagener C, Neumaier M. Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. Comparative analysis by northern blot and in situ hybridization. Am J Pathol 1997, 151(2):521-530.
7. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006, 6(6):433-446.
8. Fournes B, Sadekova S, Turbide C, Letourneau S, Beauchemin N. The CEACAM1-L Ser503 residue is crucial for inhibition of colon cancer cell tumorigenicity. Oncogene 2001, 20(2):219-230.
9. Mowery J, Hixson DC. Detection of cell-CAM 105 in the pericanalicular domain of the rat hepatocyte plasma membrane. Hepatology 1991, 13(1):47-56.
10. Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, Erickson SK, Najjar SM. CEACAM1 regulates insulin clearance in liver. Nat Genet 2002, 30(3):270-276.
11. Najjar SM, Philippe N, Suzuki Y, Ignacio GA, Formisano P, Accili D, Taylor SI. Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. Biochemistry 1995, 34(29):9341-9349.
12. Najjar SM. Regulation of insulin action by CEACAM1. Trends Endocrinol Metab 2002, 13(6):240-245.
13. Soni P, Al-Hosaini KA, Fernstrom MA, Najjar SM. Cell adhesion properties and effects on receptor-mediated insulin endocytosis are independent properties of pp120, a substrate of the insulin receptor tyrosine kinase. Mol Cell Biol Res Commun 1999, 1(2):102-108.
14. DeAngelis AM, Heinrich G, Dai T, Bowman TA, Patel PR, Lee SJ, Hong EG, Jung DY, Assmann A, Kulkarni RN, et al. Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism. Diabetes 2008, 57(9):2296-2303.
15. Dai T, Abou-Rjaily GA, Al-Share QY, Yang Y, Fernstrom MA, Deangelis AM, Lee AD, Sweetman L, Amato A, Pasquali M, et al. Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. J Biol Chem 2004, 279(43):45155-45161.
16. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
17. Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein?. Diabetologia 2000, 43(7):946-952.
18. Duckworth WC. Insulin degradation: mechanisms, products, and significance. Endocr Rev 1988, 9(3):319-345.
19. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev 1998, 19(5):608-624.
20. Duckworth WC, Hamel FG, Peavy DE. Hepatic metabolism of insulin. Am J Med 1988, 85(5A):71-76.
21. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002, 16(4):703-716.
22. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003, 14(3):137-145.
23. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 10(4):306-315.
24. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375(9733):2267-2277.
25. Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, et al. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 2006, 55(8):2357-2364.
26. DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl 2004, (143):9-21.
27. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17(1):4-12.
28. Sell H, Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?. Proc Nutr Soc 2009, 68(4):378-384.
29. Kawada T. Insulin resistance, as expressed by HOMA-R, is strongly determined by waist circumference or body mass index among Japanese working men. 59(7):1044-1046.
30. Najjar SM, Yang Y, Fernstrom MA, Lee SJ, Deangelis AM, Rjaily GA, Al-Share QY, Dai T, Miller TA, Ratnam S, et al. Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab 2005, 2(1):43-53.
31. Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord 1995, 19(Suppl 3):S27-36.
32. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84(5):1513-1517.